Rev Esp Quimioter 2022;35(Suppl.2):20-27

Antibacterial spectrum of cefiderocol

DESIRÉE GIJÓN CORDERO, JUAN ANTONIO CASTILLO-POLO, PATRICIA RUIZ-GARBAJOSA, RAFAEL CANTÓN

Published: 4 October 2022

Cefiderocol, a siderophore catechol cephalosporin, recently introduced in the market has been developed to enhance the in vitro activity of extended spectrum cephalosporins and to avoid resistance mechanisms affecting cephalosporins and carbapenems. The in vitro study of cefiderocol in the laboratory requires iron depleted media when MIC values are determined by broth microdilution. Disk diffusion presents good correlation with MIC values. In surveillance studies and in clinical trials it has been demonstrated excellent activity against Gram-negatives, including carbapenemase producers and non-fermenters such as Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Few cefiderocol resistant isolates have been found in surveillance studies. Resistance mechanisms are not directly associated with porin deficiency and or efflux pumps. On the contrary, they are related with gene mutations affecting iron transporters, AmpC mutations in the omega loop and with certain beta-lactamases such us KPC-variants determining also ceftazidime-avibactam resistance, certain infrequent extended-spectrum betalactamases (PER, BEL) and metallo-beta-lactamases (certain NDM variants and SPM enzyme).

http://www.doi.org/10.37201/req/s02.03.2022

Rev Esp Quimioter 2022; 35(Suppl. 2):20-27 [Full-text PDF]